Abstract：
Autoantibodies against type I interferon (IFN) are associated with a worse outcome in COVID-19. The measurement of cytokine-neutralizing autoantibodies has been limited, hindering understanding of their role in clinical practice. We showed that an easy and reliable assay can be reproduced and validated to measure the neutralizing potency of autoantibodies directed to type I or type II IFN. Identifying of anti-cytokine autoantibodies might reflect on early treatments for subsequent infections, such as with antivirals or virus-neutralizing monoclonal antibodies.
摘要：
抗I型干扰素（IFN）的自身抗体与COVID-19的不良结果有关。细胞因子中和自身抗体的测量受到限制，阻碍了对其在临床实践中的作用的理解。我们表明，可以复制和验证一种简单可靠的测定法，以测量针对I型或II型IFN的自身抗体的中和效力。抗细胞因子自身抗体的鉴定可能反映在随后感染的早期治疗中。例如抗病毒药物或病毒中和单克隆抗体。
